First National Corp Allakos Inc. Transaction History

First National Corp

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Jul 30, 2019	SELL	$36.0 - $44.73 $9,900 - $12,300	-275 Closed	0 $0
Q4 2018 Jun 12, 2019	BUY	$31.59 - $62.65 $8,687 - $17,228	275 New	275 $14,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $82.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of First National Corp , based on Form 13F filings with the SEC.

Stay updated on First National Corp with notifications on news.